VistaGen Therapeutics, Inc. (VTGN)

VistaGen Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is April - March.

Year Ending	TTM	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Cash & Equivalents	119.17	119.17	16.64	68.14	103.11	1.36
Cash & Cash Equivalents	119.17	119.17	16.64	68.14	103.11	1.36
Cash Growth	616.23%	616.23%	-75.58%	-33.92%	7508.91%	-89.66%
Other Current Assets	1.51	1.51	0.87	2.86	1.01	0.23
Total Current Assets	120.67	120.67	17.51	71	104.12	1.58
Property, Plant & Equipment	2.26	2.26	2.77	3.08	3.59	3.79
Other Long-Term Assets	0.73	0.73	0.82	0.57	0.58	0.4
Total Long-Term Assets	2.98	2.98	3.58	3.65	4.16	4.19
Total Assets	123.65	123.65	21.09	74.64	108.28	5.77
Accounts Payable	1.55	1.55	2.47	2.76	0.84	1.84
Deferred Revenue	3.47	3.47	3.03	2.8	3.91	0
Current Debt	0.55	0.55	0.59	0.43	0.37	0.37
Other Current Liabilities	-0.44	-0.44	-1.52	-0.23	-0.93	0.56
Total Current Liabilities	5.12	5.12	4.57	5.77	4.19	2.77
Long-Term Debt	1.57	1.57	2.12	2.61	3.35	3.72
Other Long-Term Liabilities	2.67	2.67	2.32	1.56	8.76	5.01
Total Long-Term Liabilities	4.24	4.24	4.44	4.16	12.11	8.73
Total Liabilities	9.37	9.37	9.01	9.93	16.3	11.5
Total Debt	2.12	2.12	2.71	3.04	3.72	4.09
Debt Growth	-21.80%	-21.80%	-10.78%	-18.28%	-9.12%	6043.84%
Retained Earnings	-356.21	-356.21	-326.85	-267.6	-219.84	-201.91
Shareholders' Equity	114.29	114.29	12.08	64.72	91.98	-5.73
Net Cash / Debt	117.05	117.05	13.93	65.1	99.39	-2.74
Net Cash / Debt Growth	740.43%	740.43%	-78.61%	-34.50%	-	-
Net Cash Per Share	6.05	6.05	2.00	9.86	34.62	-
Working Capital	115.55	115.55	12.93	65.23	99.93	-1.19
Book Value Per Share	5.91	5.91	1.74	9.81	32.04	-3.58

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).